


Exhibit B



IAP13 Rec'd PCT/PTO 22 JAN 2007

PCT

I hereby certify that this paper (along with any paper referred to as being attached
enclosed) is being deposited with the U.S. Postal Service on the date shown
below, with sufficient postage as First Class Mail, in an envelope addressed to:
MS. McMillian, Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450

Dated: January 19, 2007

Signature

(Nabeela R. McMillian)

Docket No.: 30986/40924
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Martin A. Crockard et al.

Application No.: 10/570,588

Confirmation No.: 7390

Filed: March 3, 2006

Art Unit: Not Yet Assigned

For: Diagnosis of Risk of Breast Cancer

Examiner: Not Yet Assigned

RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

MS Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Notice to File Missing Parts of Application – Filing Date Granted mailed November 22, 2006, Applicant respectfully submits a Combined Declaration and Power of Attorney, a Sequence Listing Diskette, a Sequence Listing Paper Copy, and Part 2 Copy of Notice.

Our check in the amount of \$130.00 covering the fee set forth in 37 CFR 1.16(f) is enclosed. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper

01/24/2007 ATRAN1 00000085 10570588


01 FC:1617

130.00 0P

hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30986/40924. A duplicate copy of this paper is enclosed.

Dated: January 19, 2007

Respectfully submitted,

By 
Nabeela R. McMillian

Registration No.: 43,363
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant

USA

DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of subject matter which is claimed and for which a patent is sought on an invention entitled

DIAGNOSIS OF RISK OF BREAST CANCER

the specification of which is attached hereto or

was filed on 2 SEP 04 as United States Application Number or PCT International Application Number PCT/GB04/03773 and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for a patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed:


Prior Foreign Application Number(s)	Country	Foreign Filing Date	Priority Not Claimed	Certified Copy Attached?
			YES	NO
0320648.9	GB	3 SEP 03	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Direct all correspondence to:
Marshall, Gerstein & Borun
6300 Sears Tower
233 South Wacker Drive
Chicago
Illinois
60606-6357
United States of America

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C 1001 and that such willful false statements may jeopardise the validity of the application or any patent issued thereon.

Full name of sole or
First Inventor Martin Andrew CROCKARD


Inventor's signature 

Residence address Co. Antrim, BT29 4QY, Northern Ireland.

Post Office address Randox Laboratories Ltd. Ardmore, Diamond Road, Crumlin
Co. Antrim, BT29 4QY, Northern Ireland.

Country of Citizenship United Kingdom Date of signature 16-05-06

Full name of
Second Inventor Janice Roberta BAILIE

Inventor's signature 

Residence address Co. Antrim, BT29 4QY, Northern Ireland.

Post Office address

Randox Laboratories Ltd. Ardmore, Diamond Road, Crumlin
Co. Antrim, BT29 4QY, Northern Ireland.

6.5.06


Country of Citizenship United Kingdom

Date of signature

Full name of

Third Inventor John Victor LAMONT

Inventor's signature



Residence address Co. Antrim, BT29 4QY, Northern Ireland.

Post Office address

Randox Laboratories Ltd. Ardmore, Diamond Road, Crumlin
Co. Antrim, BT29 4QY, Northern Ireland.

28th March 2006

Country of Citizenship United Kingdom

Date of signature

29th March 2006

Full name of
Fourth Inventor Stephen Peter FITZGERALD

Inventor's signature 

Residence address Co. Antrim, BT29 4QY, Northern Ireland.


Post Office address Randox Laboratories Ltd. Ardmore, Diamond Road, Crumlin
Co. Antrim, BT29 4QY, Northern Ireland.

Country of Citizenship United Kingdom Date of signature 15-5-06

PATENT

Attorney Docket No.: 30986/40924

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Crockard et al.) I hereby certify that this paper is being
Serial No: 10/570,588) deposited with the United States Postal
Filed: March 3, 2006) Service as first class mail, postage prepaid,
Title: Diagnosis of Risk of Breast) in an envelope addressed to Mail Stop
Cancer) Missing Parts, Commissioner for Patents,
Group Art Unit: Not Yet Assigned) P.O. Box 1450, Alexandria, VA 22313-
Examiner: Not Yet Assigned) 1450 on
DATE: January 19, 2007

Nabeela R. McMillian

STATEMENT UNDER 37 C.F.R. §§1.821(f)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

I hereby state that the content of the paper and computer-readable copies of the Sequence Listing, submitted herewith in accordance with 37 C.F.R. §§1.821 and 1.825, are the same and include no new matter.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606
(312) 474-6300

By:


Name: Nabeela R. McMillian
Registration No.: 43,363
Attorney for Applicants

Date: January 19, 2007

SEQUENCE LISTING

<110> Randox Laboratories Ltd.

<120> Diagnosis of Risk of Breast Cancer

<130> 30986/40924

<140> Not Yet Assigned

<141> 2006-03-03

<150> PCT/GB2004/003773

<151> 2003-09-03

<160> 3

<170> PatentIn version 3.3

<210> 1

<211> 513

<212> DNA

<213> Homo sapiens

<400> 1

tttatggtca taagcttaga aaatccttg cccaacataa aataagagaa ctctaatttc 60

ttagggagat ttttattaaa tgattagatt tgtagcatat agttgtataa aataagatga 120

actctaattt ctttagggagg ttttattaaa tgattagatt tgtagcatat catcggtaa 180

agtacatgga cattatttt gatatagaaa gtgttagtgg ccccttcatt gttctgagtt 240

actctcatct gtccaaacccc agcgagccac tgattattcc ctttctctga actttgtgg 300

gtttatggaa gcttcattcc tagcacgaa ggcgtcaatc attaatctcg ggtgattag 360

cctcaggcat ctccctgctc tagctgagg ggtgtggtag tggtaaagt tgcagtgc 420

tgatcacgtg gttggttcga ctggtaactg gtccctctct ggcaagagcc acctcatcag 480

tatcaactca ggaatgctgg aaatcatttt atg 513

<210> 2

<211> 138

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(138)

<400> 2

atg att aga ttt gta gca tat cat cgt gta aag tac atg gac att att 48
Met Ile Arg Phe Val Ala Tyr His Arg Val Lys Tyr Met Asp Ile Ile
1 5 10 15

ttt gat ata gaa agt gta gtg ttc ccc ttc att gtt ctg agt tac tct 96
Phe Asp Ile Glu Ser Val Val Phe Pro Phe Ile Val Leu Ser Tyr Ser
20 25 30

cat ctg tcc aac ccc agc gag cca ctg att att ccc ttt ctc 138

His Leu Ser Asn Pro Ser Glu Pro Leu Ile Ile Pro Phe Leu
35 40 45

<210> 3
<211> 46
<212> PRT
<213> Homo sapiens

<400> 3

Met Ile Arg Phe Val Ala Tyr His Arg Val Lys Tyr Met Asp Ile Ile
1 5 10 15


Phe Asp Ile Glu Ser Val Val Phe Pro Phe Ile Val Leu Ser Tyr Ser
20 25 30

His Leu Ser Asn Pro Ser Glu Pro Leu Ile Ile Pro Phe Leu
35 40 45


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 19, 2007

Signature:


(Nabeela R. McMillian)

Docket No.: 30986/40924
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Martin A. Crockard et al.

Application No.: 10/570,588

Confirmation No.: 7390

Filed: March 3, 2006

Art Unit: Not Yet Assigned

For: Diagnosis of Risk of Breast Cancer

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an

admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.


The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30986/40924. A duplicate copy of this paper is enclosed.

Dated: January 19, 2007

Respectfully submitted,

By 
Nabeela R. McMillian
Registration No.: 43,363
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant

Form PTO-1449 (Modified)

Atty. Docket No.
30986/40924Serial No.
10/570,588**INFORMATION DISCLOSURE STATEMENT**Applicant(s)
Martin A. Crockard et al.Filing Date
March 3, 2006Art Unit
Not Yet
Assigned**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation Yes	Translation No
	WO 01/92581 A2	12/06/2001	PCT	X	
	WO 02/092854 A2	11/21/2002	PCT	X	
	WO 03/061386 A1	07/31/2003	PCT	X	

OTHER DOCUMENTS

	NCBI Sequence Viewer v2.0; Search Nucleotide; Authors: B. Birren et al.; Website: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=24416019 ; Dated: March 10, 2006
	Article: Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale; Authors: Joseph L. DeRisi et al. Science Mag.-Vol. 278; Dated October 24, 1997 Website: www.sciencemag.org
	Article: Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction; Authors: Peng Liang et al.; Science, New Series, Vol. 257, No. 5072; Dated August 14, 1992; pp. 967-971; Website: http://www.jstor.org
	Clinical Chemistry 48:8 pp. 1147-1150 (2002); Cancer Diagnostics: Overview; Cancer Biomarkers: Easier Said Than Done; Author: Kenneth P. H. Pritzker
	Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical Implications; Authors: Therese Sorlie et al.; PNAS; September 11, 2001; Vol. 98; No. 19; pp. 10869-10874; Website: www.pnas.org/cgi/doi/10.1073/pnas.191367098

EXAMINER:

DATE CONSIDERED:

Form PTO-1449 (Modified)	Atty Docket No. 30986/40924	Serial No. 10/570,588
Applicant(s) Martin A. Crockard et al.		
Filing Date March 3, 2006	Art Unit Not Yet Assigned	

	Clinical Chemistry 48:8 pp 1160-1169; Vol.13, No. 3(2002); Cancer Diagnostics: Review; Proteomics for Cancer Biomarker Discovery; Authors: Pothur R. Srinivas et al.
	Clinical Microbiology Reviews; Dated: July 2000; pp. 408-427; Copyright © 2000, American Society for Microbiology: Applications of Differential-Display Reverse Transcription-PCR to Molecular Pathogenesis And Medical Mycology
	Clinical Chemistry 48:8; pp 1241-1250 (2002); Cancer Diagnostics: Discovery and Clinical Applications; Human Kallikrein gene 5 (KLK5) Expression by Quantitativr PCR: An Independent Indicator of Poor Prognosis In Breast Cancer: Authors: George M. Yousef et al.
	Proc. Natl. Acad. Sci. USA; Vol. 96, pp. 10632-10636; September 1999; Biochemistry: Messenger RNA translation state: The second dimension of high-throughput expression Screening: Authors: Qin Zong et al.

EXAMINER:	DATE CONSIDERED:
-----------	------------------



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/570,588	Martin A. Crockard	30986/40924

04743
 MARSHALL, GERSTEIN & BORUN LLP
 233 S. WACKER DRIVE, SUITE 6300
 SEARS TOWER
 CHICAGO, IL 60606

RECEIVED

COPY

DEC 07 2006

MARSHALL GERSTEIN

INTERNATIONAL APPLICATION NO.

PCT/GB04/03773

I.A. FILING DATE	PRIORITY DATE
09/02/2004	09/03/2003

CONFIRMATION NO. 7390

371 FORMALITIES LETTER



OC000000021327992

Date Mailed: 11/22/2006

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 03/03/2006
- Copy of the International Search Report filed on 03/03/2006
- Copy of IPE Report filed on 03/03/2006
- Preliminary Amendments filed on 03/03/2006
- Biochemical Sequence Listing filed on 03/03/2006
- U.S. Basic National Fees filed on 03/03/2006
- Priority Documents filed on 03/03/2006
- Specification filed on 03/03/2006
- Claims filed on 03/03/2006
- Abstracts filed on 03/03/2006
- Drawings filed on 03/03/2006
- Paper nucleotide sequence listings filed on 03/03/2006

Docketed: 1-22-07

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$130 for a Large Entity:

• **\$130 Surcharge.**

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

FREDERICK SMITH

Telephone: (703) 308-9140 EXT 210

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/570,588	PCT/GB04/03773	30986/40924

FORM PCT/DO/EO/905 (371 Formalities Notice)